GlassScriptPhysician profile
Allyse Ortega
NPI 1982149878
$2,749.65
in general payments reported to CMS, 2019-2025
22 companies · $1,073 in 2025
The $1,073 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18.81 · 2022: $112 · 2023: $925 · 2024: $622 · 2025: $1,073.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,540 · Consulting Fee: $78.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,540.46 |
| Consulting Fee | $78.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $494.78 | 2023-2025 | Tezspire |
| Amgen INC. | $457.47 | 2021-2025 | Tezspire, Uplizna, Evenity |
| Eisai INC. | $301.10 | 2023-2025 | |
| Tg Therapeutics, INC. | $230.71 | 2023-2025 | |
| Janssen Biotech, INC. | $201.37 | 2024-2025 | Tremfya, Stelara |
| Biogen, INC. | $185.00 | 2025 | Tysabri |
| Glaxosmithkline, LLC. | $120.81 | 2023 | Nucala |
| Lundbeck LLC | $119.91 | 2023-2025 | Vyepti |
| Takeda Pharmaceuticals U.S.A., INC. | $119.05 | 2024-2025 | Entyvio |
| Argenx US, INC. | $116.36 | 2024-2025 | Vyvgart |
| Csl Behring | $106.32 | 2024 | Hizentra |
| Abbvie INC. | $102.74 | 2024-2025 | |
| Invivyd INC | $27.34 | 2025 | Pemgarda |
| Medtronic, INC. | $22.89 | 2023 | Intellis Adaptivestim |
| Pfizer INC. | $22.48 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $21.50 | 2024 | Rebyota |
| Genentech USA, INC. | $20.46 | 2024 | Ocrevus Zunovo |
| Daiichi Sankyo INC. | $20.11 | 2023 | Injectafer |
| Cumberland Pharmaceuticals, INC. | $19.78 | 2023 | Vibativ |
| Adma Biomanufacturing LLC | $18.56 | 2024 | |
| Grifols USA, LLC | $14.36 | 2023 | Gamunex-C |
| Organon LLC | $6.55 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allyse Ortega listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.